DrugIn clinical trials
Divarasib
divarasib
Investigational oral next-generation KRAS G12C inhibitor (Roche). Phase 3 Krascendo 1 (NEJM, 25 October 2026): in 338 patients with previously treated KRAS G12C-mutated advanced NSCLC, median PFS 9.8 vs 5.7 months (HR 0.58) and median OS 17.7 vs 12.0 months (HR 0.56) versus sotorasib or adagrasib. Not approved.
Also in the catalogue
- Zolacabtagene autoleucelDrug
- Insulin icodecDrug
- Liu J, Yi T, Xing P, et al. Trial of Endovascular Therapy for Mild Stroke with Large-Vessel Occlusion (MILD-MT). N Engl J Med, 2026Publication
- Skoulidis F, Ahn MJ, Gadgeel S, et al. Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC (Krascendo 1). N Engl J Med, 2026Publication
- ЛорундростатDrug
- Мебуфотенин (5-MeO-DMT, BPL-003)Drug
Scales
Identifiers
- INN
- divarasib
Details
- Status
- In clinical trials
- Class
- KRAS G12C inhibitor
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.